Gilles T.’s Post

Key takeaways from LSX The LSX Nordic Congress is over after two inspiring days here in Copenhagen. While the current funding situation remains tough, we are leaving the congress with an optimistic view on the Nordic life science ecosystem. Here are our key takeaways from the congress: 💰 Funding challenges persist: The congress highlighted the ongoing difficulty in securing funding for biotech ventures. The heydays of 2020/21 are unlikely to return anytime soon. Biotech companies should prioritize strategies to extend their financial runways, streamline research programs, and maintain flexibility with both a Plan A and a Plan B. 📢 Value communication matters: While Nordic biotech companies excel in scientific innovation, many must improve their ability to convey the value of their research. Early communication of commercial value, gaps in standard of care, access pathways, and perspectives from patients, healthcare professionals, and key opinion leaders should be emphasized early in the development process. Focus on benefits, not features. 🔬 Focus on platform applications: Platform-based biotech companies should consider concentrating their efforts on one or a few select use cases that offer clear commercial potential, allowing for effective resource allocation and better foresight for investors. 🌍 Build global companies: Management teams within Nordic biotech companies should adopt a more international and diverse approach without losing their core strengths (quality of science, resilience, humbleness). This better positions Nordic biotechs to seize opportunities in the global market. Biobridge Partners remains dedicated to support the Nordic life science ecosystem and we look forward to continuing the productive dialogues initiated during the event. #LSXNordic #lifesciences #biobridgepartners

🌟 Heading to #AusBiotech2023 in Brisbane? Connect with our powerhouse team; Jay (Jaehyun) Lee, Jonghyun Park, and Jayden (Joon Hyuk) Lim, and discuss how we can help streamline your clinical trial operations to maximize its efficiency. We're excited for meetings, new connections, and socializing. Feel free to find us at the #SeoulBioHub booth or reach out via the Jublia Partnering Portal! 🤝 #AusBiotech #AusBiotech2023 #AusBio2023 #JNPMEDI #MAVEN #MavenClinicalCloud #DecentralizedClinicalTrials #DigitalClinicalTrials #ClinicalTrials #ClinicalResearch

If you work in oncology drug discovery and are attending BIO Europe in Munich, we invite you to meet with Dr. Pamela Bush to discuss how our technology can help research teams select a stronger candidate for clinical trials efficiently and with higher confidence. At Predictive Oncology, we incorporate live cell assays into active ML predictions to help you assess the strength of your discovery drug molecules against a vast heterogenous tumor sample population. Our PDEAL platform can predict drug response with 92% accuracy in tumor sample populations from within our biobank of 150K+ samples. #drugdiscovery #drugdevelopment #pharma #emergingtechnologies #biopharma #molecularbiology #oncologydrugdiscovery #oncology #machinelearning #AI  #marketaccess #artificialintelligence #digitaltransformation #cancerresearch #biotech #lifesciences 

Our second life science event was another sell-out! Learning so much about the needs of life science tenants and properties. What should we talk about next?

ARENSIA Exploratory Medicine GmbH early phase clinical InnovationXChange Europe is happening on the 16 April at the prestigious Dolder Grand Zurich Hotel. This summit will bring together more than 30 senior-level executives from some of the most innovative Pharmaceutical and Biotech companies in Europe with many thanks to our confirmed speakers and thought leaders including: - Ingeborg Heirman - Senior Director Clinical Trial Operations - Regeneron - Ulf Grawunder - CEO - T-CURX GmbH - Laura Lassouw-Polman - COO - Sairopa B.V. - Nick Clark - Executive Director Regulatory Affairs - Gilead - Inge De Clercq - Clinical Operations Development Lead - argenx - Dr. Claudia Hesselmann, PhD - CEO - ARENSIA Exploratory Medicine GmbH - Alina Jucov - Medical Director - ARENSIA Exploratory Medicine GmbH If you represent Pharma or Biotech and have an active drug developing pipeline and would like to attend drop me a line as we are close to capacity. #arensia #earlyphase #clinicaldevelopment #oncology #cns #immunology #diversity #equity #inclusion #patientrecruitment #siteactivation

Join President & CEO Thomas Kim at BIO-Europe November 6-8, where he will present on EpiVario's transformative approach towards preventing relapse in opioid use disorder patients. The presentation will cover the discovery and early development of novel small molecule inhibitors of Acetyl CoA Synthetase 2 (ACSS2), a critical enzyme in the epigenetic regulation of addiction forming neural circuits. Promising preclinical data suggests that these small molecule inhibitors could address addiction behavior in a wide range of substance use disorders, including opioid, cocaine, alcohol & nicotine addiction.” #epigenetics #neuroepigenetics #neurosciences #addictiontreatment #smokingcessation #biotechnology #opioidusedisorder #alcoholaddiction #penn

"Day 2 at BioEurope 2023 is underway! After a fantastic first day of insightful conversations and a great evening at Booth 133, we're energized and ready for more. Come join us to discuss how our GMP-compliant contract analytical services can benefit your projects. Looking forward to another day of making connections! #BioEurope2023 #GMPAnalytics #Day2"

🇧🇪 Belgium, and particularly Wallonia have an ATMP ecosystem that is unique in Europe. BioWin, and its members, have been working for months on a strategic initiative focusing on advanced therapies; disruptive approaches that open up new fields in the history of medicine by enabling patients to be cured - and no longer just treated. The objective is to bring together large companies, SMEs, research centres, universities and hospitals to consolidate the entire value chain. 👉 Read more: https://lnkd.in/ek8TrCj4

[#innaxe4eu] Zoom on insights from the Council of European BioRegions - CEBR! 🛠️ Last month, Council of European BioRegions - CEBR organized interviews and an interactive discussion on “Enhancing the impact of EU life sciences clusters actions through international cooperation” with stakeholders from the health and life science European sector to gather insights and recommendations on INNAXE’s future joint action plan.   📌 Cluster to cluster (C2C) cooperation is pivotal, grounded in mutual trust and involving cluster organizations, their companies, and stakeholders directly. 📌 EU clusters are motivated to collaborate in tackling shared challenges, demonstrating a collective commitment to innovation. 📌 Matching innovators with investors poses a significant challenge across diverse countries and ecosystems, emphasized as a top priority for many clusters. 📌 Real-world needs should inform the development of new products, with public procurement of innovation playing a role in enhancing healthcare quality and equity. 📌 European cooperation prioritizes advanced therapies and health data access, with regulatory and educational aspects taking precedence over technical considerations. Additionally, cascade funding is recognized as a valuable tool to support competitiveness, underscored by the importance of quality support provided by clusters. 🙏 Many thanks to Council of European BioRegions - CEBR BioRegions and the European ecosystem for their shared insights to consolidate our joint action plan. #innaxe4eu #Europe #innovation #health #clusters #lifescience #biotech #medtech Marta González Anaïs Le Corvec Alberto Baldi 

🤔 What are you most looking forward to learning and talking about during #BIOEUROPE? Let's talk about the role of trusted #AI in drug development. Reach out to Marianna Esposito, PhD, to connect ahead of the event.